Literature DB >> 25847620

Inhibiting cholesterol degradation induces neuronal sclerosis and epileptic activity in mouse hippocampus.

Farah Chali1, Fathia Djelti2,3, Emmanuel Eugene1, Mario Valderrama4, Catherine Marquer1, Patrick Aubourg2,3, Charles Duykaerts1, Richard Miles1, Nathalie Cartier2,3, Vincent Navarro1.   

Abstract

Elevations in neuronal cholesterol have been associated with several degenerative diseases. An enhanced excitability and synchronous firing in surviving neurons are among the sequels of neuronal death in these diseases and also in some epileptic syndromes. Here, we attempted to increase neuronal cholesterol levels, using a short hairpin RNA to suppress expression of the enzyme cytochrome P450 family 46, subfamily A, polypeptide 1 gene (CYP46A1). This protein hydroxylates cholesterol and so facilitates transmembrane extrusion. A short hairpin RNA CYP46A1construction coupled to the adeno-associated virus type 5 was injected focally and unilaterally into mouse hippocampus. It was selectively expressed first in neurons of the cornu ammonis (hippocampus) (CA)3a region. Cytoplasmic and membrane cholesterol increased, and the neuronal soma volume increased and then decreased before pyramidal cells died. As CA3a pyramidal cells died, interictal electroencephalographic (EEG) events occurred during exploration and non-rapid eye movement sleep. With time, neuronal death spread to involve pyramidal cells and interneurons of the CA1 region. CA1 neuronal death was correlated with a delayed local expression of phosphorylated tau. Astrocytes were activated throughout the hippocampus and microglial activation was specific to regions of neuronal death. CA1 neuronal death was correlated with distinct aberrant EEG activity. During exploratory behaviour and rapid eye movement sleep, EEG oscillations at 7-10 Hz (theta) could accelerate to 14-21 Hz (beta) waves. They were accompanied by low-amplitude, high-frequency oscillations of peak power at ~300 Hz and a range of 250-350 Hz. Although episodes of EEG acceleration were not correlated with changes in exploratory behaviour, they were followed in some animals by structured seizure-like discharges. These data strengthen links between increased cholesterol, neuronal sclerosis and epileptic behaviour.
© 2015 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.

Entities:  

Keywords:  cholesterol; cytochrome P450 family 46 subfamily A; epilepsy; neurodegeneration

Mesh:

Substances:

Year:  2015        PMID: 25847620      PMCID: PMC4439180          DOI: 10.1111/ejn.12911

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  50 in total

1.  Analysis of dynamic brain imaging data.

Authors:  P P Mitra; B Pesaran
Journal:  Biophys J       Date:  1999-02       Impact factor: 4.033

Review 2.  Pathological basal ganglia activity in movement disorders.

Authors:  T Wichmann; J O Dostrovsky
Journal:  Neuroscience       Date:  2011-06-22       Impact factor: 3.590

3.  Propagation of tau pathology in a model of early Alzheimer's disease.

Authors:  Alix de Calignon; Manuela Polydoro; Marc Suárez-Calvet; Christopher William; David H Adamowicz; Kathy J Kopeikina; Rose Pitstick; Naruhiko Sahara; Karen H Ashe; George A Carlson; Tara L Spires-Jones; Bradley T Hyman
Journal:  Neuron       Date:  2012-02-23       Impact factor: 17.173

4.  Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons.

Authors:  M Simons; P Keller; B De Strooper; K Beyreuther; C G Dotti; K Simons
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

5.  Cholesterol loss during glutamate-mediated excitotoxicity.

Authors:  Alejandro O Sodero; Joris Vriens; Debapriya Ghosh; David Stegner; Anna Brachet; Marta Pallotto; Marco Sassoè-Pognetto; Jos F Brouwers; J Bernd Helms; Bernhard Nieswandt; Thomas Voets; Carlos G Dotti
Journal:  EMBO J       Date:  2012-02-17       Impact factor: 11.598

6.  Effects of focal injection of kainic acid into the mouse hippocampus in vitro and ex vivo.

Authors:  Caroline Le Duigou; Lucia Wittner; Lydia Danglot; Richard Miles
Journal:  J Physiol       Date:  2005-10-20       Impact factor: 5.182

7.  Inhibitory control of local excitatory circuits in the guinea-pig hippocampus.

Authors:  R Miles; R K Wong
Journal:  J Physiol       Date:  1987-07       Impact factor: 5.182

8.  Hippocampal and entorhinal cortex high-frequency oscillations (100--500 Hz) in human epileptic brain and in kainic acid--treated rats with chronic seizures.

Authors:  A Bragin; J Engel; C L Wilson; I Fried; G W Mathern
Journal:  Epilepsia       Date:  1999-02       Impact factor: 5.864

9.  Localization of temporal lobe foci by ictal EEG patterns.

Authors:  J S Ebersole; S V Pacia
Journal:  Epilepsia       Date:  1996-04       Impact factor: 5.864

10.  Preservation of topography in the connections between the subiculum, field CA1, and the entorhinal cortex in rats.

Authors:  N Tamamaki; Y Nojyo
Journal:  J Comp Neurol       Date:  1995-03-13       Impact factor: 3.215

View more
  11 in total

1.  Mapping of the Allosteric Site in Cholesterol Hydroxylase CYP46A1 for Efavirenz, a Drug That Stimulates Enzyme Activity.

Authors:  Kyle W Anderson; Natalia Mast; Jeffrey W Hudgens; Joseph B Lin; Illarion V Turko; Irina A Pikuleva
Journal:  J Biol Chem       Date:  2016-04-07       Impact factor: 5.157

2.  Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.

Authors:  Natalia Mast; Aicha Saadane; Ana Valencia-Olvera; James Constans; Erin Maxfield; Hiroyuki Arakawa; Young Li; Gary Landreth; Irina A Pikuleva
Journal:  Neuropharmacology       Date:  2017-06-24       Impact factor: 5.250

Review 3.  Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases.

Authors:  Alexey M Petrov; Irina A Pikuleva
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

4.  In vitro cytochrome P450 46A1 (CYP46A1) activation by neuroactive compounds.

Authors:  Natalia Mast; Kyle W Anderson; Kevin M Johnson; Thanh T N Phan; F Peter Guengerich; Irina A Pikuleva
Journal:  J Biol Chem       Date:  2017-06-22       Impact factor: 5.157

5.  Clinico-biological markers for the prognosis of status epilepticus in adults.

Authors:  Aurélie Hanin; Sophie Demeret; Virginie Lambrecq; Benjamin Rohaut; Clémence Marois; Meriem Bouguerra; Alexandre Demoule; Jean-Louis Beaudeux; Randa Bittar; Jérôme Alexandre Denis; Françoise Imbert-Bismut; Foudil Lamari; Benoit Rucheton; Dominique Bonnefont-Rousselot; Mario Chavez; Vincent Navarro
Journal:  J Neurol       Date:  2022-06-29       Impact factor: 6.682

6.  Endogenous 24S-hydroxycholesterol modulates NMDAR-mediated function in hippocampal slices.

Authors:  Min-Yu Sun; Yukitoshi Izumi; Ann Benz; Charles F Zorumski; Steven Mennerick
Journal:  J Neurophysiol       Date:  2015-12-23       Impact factor: 2.714

7.  Can a hypercholesterolemic diet change the basal brain electrical activity and during status epilepticus in rats?

Authors:  Romildo de Albuquerque Nogueira; Daniella Tavares Pessoa; Eva Luana Almeida da Silva; Edbhergue Ventura Lola Costa
Journal:  Metab Brain Dis       Date:  2018-09-26       Impact factor: 3.584

Review 8.  Cholesterol Hydroxylating Cytochrome P450 46A1: From Mechanisms of Action to Clinical Applications.

Authors:  Irina A Pikuleva; Nathalie Cartier
Journal:  Front Aging Neurosci       Date:  2021-07-08       Impact factor: 5.750

9.  Neuronal Cholesterol Accumulation Induced by Cyp46a1 Down-Regulation in Mouse Hippocampus Disrupts Brain Lipid Homeostasis.

Authors:  Sophie Ayciriex; Fathia Djelti; Sandro Alves; Anne Regazzetti; Mathieu Gaudin; Jennifer Varin; Dominique Langui; Ivan Bièche; Eloise Hudry; Delphine Dargère; Patrick Aubourg; Nicolas Auzeil; Olivier Laprévote; Nathalie Cartier
Journal:  Front Mol Neurosci       Date:  2017-07-11       Impact factor: 5.639

10.  In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.

Authors:  Natalia Mast; Peter Verwilst; Clayton J Wilkey; F Peter Guengerich; Irina A Pikuleva
Journal:  J Med Chem       Date:  2019-11-03       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.